Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Viva Gold Reports Multiple High-Grade Gold Hits at the Tonopah Gold Project (click to learn more) Xcyte Digital Corp. Signs Agreement to Purchase Assets of Webinar.net (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Avalo Therapeutics Inc AVTX

Healthcare Biotechnology
Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The Company's lead asset is AVTX-009, an anti-IL-1ß mAb, targeting inflammatory diseases. Its pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein). AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1ß (IL-1ß... see more

Recent & Breaking News (NDAQ:AVTX)

Cerecor to Participate in Upcoming Healthcare Conferences

GlobeNewswire September 26, 2018

Cerecor to Acquire Ichorion Therapeutics

GlobeNewswire September 25, 2018

Cerecor CEO to Present at the H.C. Wainwright Global Investment Conference

GlobeNewswire August 31, 2018

Cerecor Reports Second Quarter 2018 Financial Results

GlobeNewswire August 9, 2018

Cerecor Announces First Patient Enrolled in Phase I Trial for Neurogenic Orthostatic Hypotension (nOH) in Parkinson’s Disease

GlobeNewswire August 1, 2018

Cerecor Announces Expansion of Leadership Team

GlobeNewswire July 16, 2018

BioDelivery Sciences Announces Agreement with Broadfin Capital on Comprehensive Plan to Strengthen Business

GlobeNewswire May 17, 2018

Cerecor Reports First Quarter 2018 Financial Results

GlobeNewswire May 11, 2018

Cerecor Appoints Simon Pedder to its Board of Directors

MarketWire Canada April 9, 2018

Cerecor Inc. Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2017

MarketWire Canada April 2, 2018

Cerecor Appoints Peter Greenleaf as Chief Executive Officer

MarketWire Canada March 28, 2018

Cerecor to Acquire Avadel Pharmaceuticals' Pediatric Assets

Marketwired February 12, 2018

Cerecor Announces Leadership Changes

Marketwired November 17, 2017

Cerecor Acquires TRx Pharmaceuticals

MarketWire Canada November 17, 2017

Cerecor Inc. Reports Third Quarter 2017 Financial Results

MarketWire Canada November 6, 2017

Cerecor, Inc. Regains Compliance with NASDAQ Minimum Bid Price Requirement

MarketWire Canada October 18, 2017

Stock Performance Review on Biotech Industry -- Vertex Pharma, Axovant Sciences, Cerecor, and Ocular Therapeutix

PR Newswire September 28, 2017

Stock Performance Review on Biotech Industry -- Radius Health, Abeona Therapeutics, Catalyst Biosciences, and Cerecor

PR Newswire August 17, 2017

Cerecor Inc. Announces Retirement of Dr. Uli Hacksell as President and Chief Executive Officer

MarketWire Canada August 14, 2017

Cerecor Inc. Reports Second Quarter 2017 Financial Results

Marketwired August 14, 2017